Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE-BC3)
NCT02793622Phase 3Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dihydroartemisinin + piperaquine in malaria (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Number of Participants Who Deliver With a Composite Adverse Birth Outcome, Incidence of Malaria in Infants at 12 months and 1 more. Started Sep 2016; status: completed.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02793622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02793622.